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Abstract Article Info 
Introduction: Nasopharyngeal carcinoma is the most found head and neck cancer, which originated from a 
nasopharyngeal epithelial cell, and predilection site commonly at rosen muller fossa. S100 protein inflammatory 
mediators are involved in the regulation of cellular processes including inflammation and malignancy. S100 
protein plays a central role in the proliferation, regulation of cell apoptosis and metastasis causing continuing 
growth of cancer cells through activation of STAT3 by IL-6, NF-κB, ROS. 
Objective: This study aimed to determine the correlation between S100 protein expression levels to the clinical 
stage of NPC WHO type III. 
Method: This research is a cross-sectional analytic study. This study was held in the Anatomical Pathology 
Department of Hasan Sadikin Hospital from August until October 2015. The study was conducted using 29 
pieces of secondary data, medical records and paraffin blocks anatomical pathology of NPC patients were 
examined S100 protein immunohistochemistry. 
Result: This study was performed from 29 subjects (18 males and 9 females). There was a strong positive 
correlation between histoscore S100 protein expression with clinical staging p<0.05. There is a significant 
correlation between S100 protein expression with the clinical stage of NPC WHO type III using double 
regression analysis (F=15.676, p=0.000). 
Conclusion: There were significant correlation S100 protein expression levels to clinical stage nasopharyngeal 
carcinoma WHO type III. 
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Nasopharyngeal carcinoma (NPC) is the most found malignant tumor 
in the head and neck area originating from nasopharyngeal epithelial cells 
[1]. The highest incidence of NPC was found in Guangdong Province of 
South China with a frequency of 100 times more than the Caucasians which 
is 17.8 per 100,000 population per year. In Indonesia, NPC is in the fourth 
place of all malignancies and is ranked first in the field of Ear Nose Throat 
Health Head and Neck Surgery. The incidence of NPC in Indonesia is 6.7 
per 100,000 populations per year with the highest age incidence of 4-5 
decades, the ratio between men and women is 2-3: 1. The prevalence of NPC 
in the Department Otorhinolaryngology Head and Neck Surgery Dr. Hasan 
Sadikin Bandung during the period of 2010-2014 was 39.4% [2-5]. 
Nasopharyngeal carcinoma is still difficult to diagnose because the hidden 
nasopharyngeal location and initial clinical symptoms are not typical. Most 
NPC patients come with complaints of advanced neck lymph nodes so that 
the prognosis becomes worse [1-6]. 
The S100 protein is an inflammatory mediator released due to infection 
or inflammation as a danger signal. The high level of S100 protein is a sign 
of repeated infection and inflammatory reactions that can be found in tumor 
epithelium. Tsuji's research in 2006 stated that lymphocyte infiltration in 
NPC would cause an increase in S100 protein which is characterized by the 
distribution of Langerhans cells and reticulum [7, 8]. The infected 
nasopharyngeal epithelium VEB provides an increased response to 
interleukin-6 that involves the signal transducer activation activator of 
transcription 3 to promote growth and invasive factors [9]. The response is 
mediated by granulocyte activity involved in the process of NPC by 
inflammation. S100 protein is a protein found in granulocytes and 
macrophages. In the inflammatory process, reactive oxygen species are 
formed. Increased ROS levels will cause activation of transcription factors 
such as NF-κB. Nuclear Factor-Kappa B has a role in cell immortality. An 
increase in NF-κB is followed by an increase in IL-6 and S100 protein 
indicating a malignancy process. Besides, that ROS will also damage DNA 
so that it promotes cell proliferation or suppresses apoptosis [10-13]. This 
process results in loose bonds. Some S100 proteins are affected by the 
process, so they are used as specific target proteins. 
In the metastatic process of NPC, S100 protein is a mediator of p53 as 
a tumor suppressor gene. In NPC, high levels of p53 were found according 
to their stage so that they could predict an increase in expression of S100 
protein found in tumor tissue and neck KGB of NFF18 patients. In a study 
in 2012, by Maletzki, expression of S100 protein was obtained from the 
presence of langerhans cells in carcinoma. Langerhans cells can be detected 
not only in the epidermis but also in the esophageal, tonsillar, 
nasopharyngeal, and lymphoid tissue epithelium. In NPC there is an 
increase in the number of Langerhans cells according to the tumor 
infiltration [7, 8, 10, 14]. 
From a immunohistochemical examination of S100 protein, we can 
identify Langerhans cells in both mature and immature forms. The picture 
of Langerhans cells at various stages in NPC shows tumor infiltration 
according to their progression. Progressivity was assessed based on the 
clinical stage, and the degree of expression of S100 protein that appeared by 
Langerhans cells from immunohistochemical examination [7, 8, 10, 14]. 
S100 protein examination by immunohistochemistry has advantages over 
other examinations, which are easier, not invasive, and cheaper. 
2. MATERIAL AND METHODS 
This research is a cross-sectional analytic study and was held in 
Anatomical Pathology Department of Hasan Sadikin Hospital from August 
until October 2015. The study was conducted using 29 pieces of secondary 
data, medical records and paraffin blocks anatomical pathology of NPC 
patients were examined S100 protein immunohistochemistry. 
 








The results of examination of S100 protein expression in WHO type III 
NPC patients who performed immunohistochemistry based on table 1, the 
distribution of 51-80% as many as 2 people (6.9%), and 27 people (93.1%) 
in distribution >80%. In the assessment based on intensity, there was a weak 
intensity of 5 people (17.2%). Moderate intensity was found in 8 people 
(27.6%), and a strong intensity of 16 people (55.2%).  
Table 1. Results for Examination of S100 Protein Expressions in WHO 
type III NPC patients 
Expressions Results % 
Distribution   
50-80 % 2 6.9 
80% 27 93.1 
Intensity    
Weak 5 17.2 
moderates 8 27.6 
strong 16 55.2 
Hystoscor   
Mean : 9.2 (3.07)   
Median: 9   
range: 4-12   
 
Table 2. Distribution of S100 proteins according to WHO type III NPC 
stages 
Distribution Stadium Results P 
I II III IV 
<20% 0 0 0 0 0  
20-50% 0 0 0 0 0 0.791 
51-80% 0 0 2 0 2  
>80% 2 6 8 11 27  
Spearman test P<0.005  
Table 2 shows the amount of S100 protein distribution according to the 
stage. From the data obtained in stage I there were 2 subjects with S100 
protein distribution >80%. In stage II there were 6 subjects with S100 
protein distribution >80%. Stage III there are 2 subjects with a distribution 
of 51-80% and 8 subjects distributed >80%, and at stage IV distribution of 
S100 protein >80%. With the Spearman statistical test, the value of p=0.791 
showed that there was no relationship between the distribution of S100 
protein and the clinical stage. 
Table 3. S100 protein intensity in WHO type III NPC patients 
Intensity Stadium Results P 
I II III IV 
Weaks 2 3 0 0 5  
Moderates 0 2 4 2 8 0.000 
Strong 0 1 6 9 16  
Spearman test P<0.05 
Table 3 shows the S100 protein intensity according to the stage. In stage 
I there were 2 subjects with weak intensity. Stage II there are 3 subjects with 
weak intensity, 2 subjects of moderate intensity, and 1 subject with strong 
intensity. Stage III there are 4 subjects with moderate intensity and 6 
subjects with strong intensity. In stage IV there are 2 subjects with moderate 
intensity and 9 subjects with strong intensity. With the Spearman statistical 
test, the intensity ratio based on the clinical stage obtained with a value of 
p=0.000, there is a significant relationship between the comparison of S100 
protein intensity to the clinical stage. 
Table 4. Histoscore results 
Histoscore Stadium Results P 
 I  II  III  IV 
Negatif 0 0 0 0 0  
Weak 0 0 0 0 0 0.000 
Moderate 2 3 0 0 5  
Strong 0 3 10 11 24  
Spearman test P<0.05 
Table 4 shows histoscore results in WHO type III NPC patients. From 
the data obtained in stage I histories with moderate positive as many as 2 
subjects. In stage II, moderately positive and strong positive histories were 
obtained for each of the 3 study subjects. In stage III there were 10 positive 
positive histories in the study subjects. With the Spearman statistical test 
obtained a comparison of the S100 protein histories based on the clinical 
stage with a value of p=0.000, there is a significant relationship between the 
comparison of S100 protein histories to the clinical stage. 
Table 5. The relationship between age, sex, and expression of S100 
protein with clinical stage 
Variabel Koefisien B SE (B) Value t Value P    Anova 
test 
Age  -.019 0.009 -2.086 0.047 - 
Sex 0.438 0.226 1.939 0.064 F: 15.676 
Protein S100 0.190 0.040 4.724 0.000 p: 0.000 
konstanta 1.489 0.723 2.060 - - 
r2 (%)=65.3%; SE : Standard Error 
Table 5 explains the relationship between age, sex, and expression of 
S100 protein with a clinical stage based on multiple regression analysis, 
with the results of the B coefficient S100 protein expression= 0.190, with a 
value of t=4.724 and p=0.000. With the ANOVA test, get the Fischer 
statistical value =15.676 and a significant value of 0.000. 
4. DISCUSSION 
From the data of S100 protein expression, it was found that the 
distribution of 50-80% amounted to 6.9% and >80% as much as 93.1%. The 
amount of S100 protein distribution according to the stage, from the data 
obtained in stage I there were 2 subjects with S100 protein distribution 
>80%. In stage II there were 6 subjects with S100 protein distribution >80%. 
Stage III there are 2 subjects with a distribution of 51-80% and 8 subjects 
distributed >80%, and at stage IV distribution of S100 protein >80%. With 
the Spearman statistical test, the value of p=0.791 showed that there was no 
relationship between the distribution of S100 protein and the clinical stage. 
On examination of the S100 protein intensity, we found a weak intensity 
of 17.2%, moderate 27.6% and strong 55.2%. Based on the stage of the 
number of subjects S100 protein intensity in stage I, there were 2 subjects 
with weak intensity. Stage II there are 3 subjects with weak intensity, 2 
subjects of moderate intensity, and 1 subject with strong intensity. Stage III 
there are 4 subjects with moderate intensity and 6 subjects with strong 
intensity. In stage IV there are 2 subjects with moderate intensity and 9 
subjects with strong intensity. With the Spearman statistical test, the 
intensity ratio based on the clinical stage obtained with a value of p=0.000, 
there is a significant relationship between the comparison of S100 protein 
intensity to the clinical stage. 
Histoscore results were based on stages of WHO type III NPC patients, 
from data obtained in stage I histories with moderate positive as many as 2 
subjects. In stage II, moderately positive and strong positive histories were 
obtained for each of the 3 study subjects. In stage III there were 10 positive 
histories in the study subjects. In stage IV the positive histories were 11 
subjects, with a value of p<0.005 with a mean of 9.2, median 9, and a range 
of 4-12. This shows a strong positive imunoexpressive result. 
The relationship between the expression level of S100 protein and 
clinical stage based on multiple regression analysis showed that the 
expression of S100 protein with a coefficient B= 0.190, t= 4.724 and 
p<0.005. The regression equation is clinical stage= 1,489-
0.019*age+0.438*sex+0.190*protein S100 (r2%=63.3%). In the Anova 
statistical test, the Fischer value of 15,676 and sig was obtained. The p-value 
0.000 in the regression model means that this multiple regression analysis 
models are significant. In this study, it was found that there was a correlation 
between the levels of expression of S100 protein towards the clinical stage 
of WHO type III KNF which was significantly based on the multiple 
regression analysis tests. From histopathology a score of 9.2 was obtained 
which gave a strong positive result so it can be concluded that the correlation 
between the expression levels of S100 protein to the clinical stage of the 
KNF WHO type III was positively strong 
These results are in accordance with Tsuji et al. research in 2006 
regarding the effect of RAGE by LMP1 on metastatic GB patients with 
nasopharyngeal carcinoma. In this study, 42 paraffin blocks of NPC patients 
consisting of 3 patients without enlarged KGB and 33 patients with nodes 
enlargement (N1-3) were then analyzed and stained by 
immunohistochemistry. The result is RAGE expression>20% in 29 subjects 
with p=0.0093 after Mann-Whitney test. In this study, it was concluded that 
there was a relationship between the expression of RAGE and metastatic 
nodes patients with NPC [11]. 
The study by Maletzki et al. In 2012 stated that the S100 protein was 
used as a diagnostic and prognostic factor in colorectal and hepatocellular 
malignancies where there was an increase in the expression of S100 protein 
from the prenacolic phase until metastasis occurred. This was concluded 
after finding 161 articles over a 10-year study of the expression of S100 







proteins in various malignancies related to poor differentiation, progression, 
advanced stage, and metastatic growth. Expression of S100 protein is 
considered a poor prognostic factor in some cancers [15]. 
5. CONCLUSION 
There were significant correlation between S100 protein expression 
levels to clinical stage nasopharyngeal carcinoma WHO type III. 
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